Biomaterial Database

Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies. 2022

Rebecca Adams, and Gabriel Osborn, and Bipashna Mukhia, and Roman Laddach, and Zena Willsmore, and Alicia Chenoweth, and Jenny L C Geh, and Alastair D MacKenzie Ross, and Ciaran Healy, and Linda Barber, and Sophia Tsoka, and Victoria Sanz-Moreno, and Katie E Lacy, and Sophia N Karagiannis

St. John's Institute of Dermatology, School of Basic & Medical Biosciences, King's College London, Guy's Hospital, London, UK.

The application of monoclonal antibodies (mAbs) for the treatment of melanoma has significantly improved the clinical management of this malignancy over the last decade. Currently approved mAbs for melanoma enhance T cell effector immune responses by blocking immune checkpoint molecules PD-L1/PD-1 and CTLA-4. However, more than half of patients do not benefit from treatment. Targeting the prominent myeloid compartment within the tumor microenvironment, and in particular the ever-abundant tumor-associated macrophages (TAMs), may be a promising strategy to complement existing therapies and enhance treatment success. TAMs are a highly diverse and plastic subset of cells whose pro-tumor properties can support melanoma growth, angiogenesis and invasion. Understanding of their diversity, plasticity and multifaceted roles in cancer forms the basis for new promising TAM-centered treatment strategies. There are multiple mechanisms by which macrophages can be targeted with antibodies in a therapeutic setting, including by depletion, inhibition of specific pro-tumor properties, differential polarization to pro-inflammatory states and enhancement of antitumor immune functions. Here, we discuss TAMs in melanoma, their interactions with checkpoint inhibitor antibodies and emerging mAbs targeting different aspects of TAM biology and their potential to be translated to the clinic.

UI	MeSH Term	Description	Entries
D007167	Immunotherapy	Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.	Immunotherapies
D008545	Melanoma	A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)	Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D010969	Plastics	Polymeric materials (usually organic) of large molecular weight which can be shaped by flow. Plastic usually refers to the final product with fillers, plasticizers, pigments, and stabilizers included (versus the resin, the homogeneous polymeric starting material). (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)	Plastic
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000074322	Antineoplastic Agents, Immunological	Antineoplastic agents containing immunological agents (e.g. MAbs). These pharmacologic preparations inhibit or prevent the proliferation of NEOPLASMS.	Antineoplastic MAbs,Antineoplastics, Monoclonal Antibodies,Antineoplastics, Monoclonal Antibody,MAbs, Antineoplastic,Monoclonal Antibodies, Antineoplastic,Antibodies Antineoplastics, Monoclonal,Antineoplastic Monoclonal Antibodies,Immunological Antineoplastic Agents,Monoclonal Antibodies Antineoplastics,Monoclonal Antibody Antineoplastics
D000082102	Immune Checkpoint Proteins	Immunomodulators that regulate immune system either in stimulatory or inhibitory fashion allowing IMMUNE TOLERANCE. Activation of suppressed immune system (IMMUNOSUPPRESSION (PHYSIOLOGY)) in immunotherapy by IMMUNE CHECKPOINT INHIBITORS often targets inhibitory checkpoint molecules.	Immune Checkpoint Molecule,Immune Checkpoint Molecules,Immune Checkpoint Protein,Inhibitory Checkpoint Molecule,Inhibitory Checkpoint Molecules,Stimulatory Checkpoint Molecule,Stimulatory Checkpoint Molecules,Checkpoint Molecule, Immune,Checkpoint Molecule, Inhibitory,Checkpoint Molecule, Stimulatory,Checkpoint Protein, Immune,Molecule, Immune Checkpoint,Protein, Immune Checkpoint
D000084582	Tumor-Associated Macrophages	Various macrophages found in TUMOR MICROENVIRONMENT. They may interact with tumor cells to influence growth and NEOPLASTIC PROCESSES.	Tumor-Associated Macrophage,Macrophage, Tumor-Associated,Tumor Associated Macrophage,Tumor Associated Macrophages
D000096142	Melanoma, Cutaneous Malignant	A primary melanoma that originates from atypical skin MELANOCYTES, especially from acquired and congenital MELANOCYTIC NEVI, and DYSPLASTIC NEVI.	FAMMM Syndrome,Familial Atypical Mole-Malignant Melanoma Syndrome,Dysplastic Nevus Syndrome, Hereditary,Melanoma, Familial,Cutaneous Malignant Melanoma,Cutaneous Malignant Melanomas,FAMMM Syndromes,Familial Atypical Mole Malignant Melanoma Syndrome,Familial Melanoma,Familial Melanomas,Malignant Melanoma, Cutaneous,Malignant Melanomas, Cutaneous,Melanomas, Cutaneous Malignant,Melanomas, Familial,Syndrome, FAMMM,Syndromes, FAMMM
D000911	Antibodies, Monoclonal	Antibodies produced by a single clone of cells.	Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D012878	Skin Neoplasms	Tumors or cancer of the SKIN.	Cancer of Skin,Skin Cancer,Cancer of the Skin,Neoplasms, Skin,Cancer, Skin,Cancers, Skin,Neoplasm, Skin,Skin Cancers,Skin Neoplasm